hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06342427 id: 23228/DESTINEX briefTitle: Stomach Cancer Exosome-based Detection acronym: DESTINEX overallStatus: RECRUITING date: 2023-03-15 date: 2025-03-15 date: 2025-03-15 date: 2024-04-02 date: 2024-04-02 name: City of Hope Medical Center class: OTHER briefSummary: Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer. conditions: Gastric Cancer conditions: Gastric Adenocarcinoma conditions: Gastric Cancer Stage conditions: Gastric Neoplasm conditions: Gastric Lesion conditions: Gastric Cancer in Situ conditions: Gastric Cancer Stage IV conditions: Gastric Cancer Stage IIIB conditions: Gastric Cancer Stage III conditions: Gastric Cancer Stage IB conditions: Gastric Cancer Stage IA conditions: Gastric Cancer, Stage 0 conditions: Gastric Cancer Stage IIIA conditions: Gastric Cancer Stage II conditions: Gastric Cancer TNM Staging conditions: Gastric Cancer Metastatic to Lung conditions: Gastric Cancer Metastatic to Liver conditions: Gastric Cancer Stage I conditions: Gastric Cancer TNM Staging Primary Tumor (T) T2B studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 800 type: ESTIMATED name: DESTINEX measure: Sensitivity measure: Specificity measure: Proportion of correct predictions (true positives and true negatives) among the total cases (i.e., accuracy) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: City of Hope Medical Center status: RECRUITING city: Duarte state: California zip: 91010 country: United States name: Ajay Goel, PhD role: CONTACT phone: 626-218-3452 email: AJGOEL@COH.ORG name: Silei Sui role: PRINCIPAL_INVESTIGATOR name: Caiming Xu role: SUB_INVESTIGATOR name: Ajay Goel, PhD role: PRINCIPAL_INVESTIGATOR lat: 34.13945 lon: -117.97729 facility: Nagoya University status: RECRUITING city: Nagoya country: Japan name: Yasuhiro Kodera role: CONTACT name: Yasuhiro Kodera role: SUB_INVESTIGATOR name: Mitsuo Kanda role: SUB_INVESTIGATOR lat: 35.18147 lon: 136.90641 facility: Mie University status: RECRUITING city: Tsu country: Japan name: Yuji Toiyama role: CONTACT name: Yuji Toiyama role: SUB_INVESTIGATOR name: Yoshinaga Okugawa role: SUB_INVESTIGATOR lat: 34.73333 lon: 136.51667 hasResults: False
nctId: NCT06342414 id: 23228/ELUCIDATE briefTitle: An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer acronym: ELUCIDATE overallStatus: RECRUITING date: 2024-03-15 date: 2025-03-15 date: 2025-03-15 date: 2024-04-02 date: 2024-04-02 name: City of Hope Medical Center class: OTHER briefSummary: It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery. conditions: Hepatocellular Carcinoma conditions: Intrahepatic Cholangiocarcinoma conditions: Cholangiocarcinoma conditions: Primary Liver Cancer conditions: Primary Liver Carcinoma conditions: Hepatic Cancer conditions: Hepatic Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED name: ELUCIDATE measure: Sensitivity measure: Specificity measure: Proportion of correct predictions (true positives and true negatives) among the total number of cases (i.e., accuracy) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: City of Hope Medical Center status: RECRUITING city: Duarte state: California zip: 91010 country: United States name: Ajay Goel, PhD role: CONTACT phone: 626-218-3452 email: AJGOEL@COH.ORG name: Caiming Xu, MD, PhD role: SUB_INVESTIGATOR name: Yoh Asahi, MD role: PRINCIPAL_INVESTIGATOR name: Ajay Goel, PhD role: PRINCIPAL_INVESTIGATOR lat: 34.13945 lon: -117.97729 facility: Graduate School of Medical Sciences, Kyushu University status: RECRUITING city: Fukuoka country: Japan name: Tomoharu Yoshizumi role: CONTACT name: Tomoharu Yoshizumi role: SUB_INVESTIGATOR name: Takeo Toshima role: SUB_INVESTIGATOR lat: 33.6 lon: 130.41667 facility: Graduate School of Medical Sciences, Kumamoto University status: RECRUITING city: Kumamoto country: Japan name: Hideo Baba role: CONTACT name: Hideo Baba role: SUB_INVESTIGATOR lat: 32.80589 lon: 130.69182 facility: Hokkaido University Graduate School of Medicine status: RECRUITING city: Sapporo country: Japan name: Akinobu Taketomi role: CONTACT name: Akinobu Taketomi role: PRINCIPAL_INVESTIGATOR name: Yoh Asahi role: PRINCIPAL_INVESTIGATOR name: Tatsuhiko Kakisaka role: SUB_INVESTIGATOR lat: 43.06667 lon: 141.35 facility: Tokushima University status: RECRUITING city: Tokushima country: Japan name: Mitsuo Shimada role: CONTACT name: Mitsuo Shimada role: SUB_INVESTIGATOR name: Katsuki Miyazaki role: SUB_INVESTIGATOR lat: 34.06667 lon: 134.56667 hasResults: False
nctId: NCT06342401 id: 23228/ENCODE briefTitle: Early Onset Colorectal Cancer Detection acronym: ENCODE overallStatus: RECRUITING date: 2023-04-15 date: 2025-04-15 date: 2025-10-15 date: 2024-04-02 date: 2024-04-02 name: City of Hope Medical Center class: OTHER briefSummary: Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women.
This study aims to detect EOCRC with a non-invasive test, using a blood-based molecular assay based on microRNA (ribonucleic acid) conditions: Colorectal Cancer conditions: Colorectal Neoplasms conditions: Colorectal Adenocarcinoma conditions: Colorectal Cancer Stage I conditions: Colorectal Cancer Stage IV conditions: Colorectal Cancer Stage II conditions: Colorectal Cancer Stage III conditions: Colorectal Neoplasms Malignant studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED name: ENCODE measure: Sensitivity measure: Specificity measure: Proportion of correct predictions (true positives and true negatives) among the total cases (i.e., accuracy) sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: City of Hope Medical Center status: RECRUITING city: Duarte state: California zip: 91010 country: United States name: Ajay Goel, PhD role: CONTACT phone: 626-218-3452 email: AJGOEL@COH.ORG name: Alessandro Mannucci, MD role: PRINCIPAL_INVESTIGATOR lat: 34.13945 lon: -117.97729 facility: IRCCS San Raffaele status: RECRUITING city: Milan country: Italy name: Giulia Martina Cavestro, MD, PhD role: CONTACT email: cavestro.giuliamartina@hsr.it name: Alessandro Mannucci, MD role: PRINCIPAL_INVESTIGATOR name: Giulia Martina Cavestro, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 facility: Kawasaki University status: RECRUITING city: Kawasaki country: Japan lat: 35.52056 lon: 139.71722 facility: Mie University status: RECRUITING city: Mie country: Japan facility: National Cancer Center Hospital status: RECRUITING city: Tokyo country: Japan lat: 35.6895 lon: 139.69171 facility: Tokyo Medical and Dental University status: RECRUITING city: Tokyo country: Japan lat: 35.6895 lon: 139.69171 facility: Yamagata University status: RECRUITING city: Yamagata country: Japan lat: 38.23333 lon: 140.36667 facility: Barcelona University status: RECRUITING city: Barcelona country: Spain name: Francesc Balaguer, MD, PhD role: CONTACT email: fprunes@clinic.cat lat: 41.38879 lon: 2.15899 facility: University of La Laguna status: RECRUITING city: La Laguna country: Spain lat: 28.4853 lon: -16.32014 facility: Salamanca Biomedical Research Institute status: RECRUITING city: Madrid country: Spain name: Jose Perea, MD role: CONTACT email: josepereag@hotmail.com name: Jose Perea, MD role: SUB_INVESTIGATOR lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06342388 id: 2024-0427 id: A538500 type: OTHER domain: UW- Madison id: Protocol Version 3/20/2024 type: OTHER domain: UW- Madison id: SMPH/POP HEALTH SCI/POP HLTH type: OTHER domain: UW- Madison briefTitle: Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage overallStatus: WITHDRAWN date: 2024-07 date: 2026-03 date: 2026-06 date: 2024-04-02 date: 2024-04-09 name: University of Wisconsin, Madison class: OTHER name: Covering Wisconsin briefSummary: The goal of this study is to try new outreach methods to improve access to Medicaid for those who lost Medicaid for procedural reasons. The main questions it aims to answer are:
2. What is the effectiveness of outreach using a live call rather than a pre-recorded call? conditions: No Medicaid Coverage studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 0 type: ACTUAL measure: Number of people who successfully renew their Medicaid coverage within 3 months of receiving the live outbound call measure: Duration of coverage gaps measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the live outbound call measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the pre-recorded outbound call sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06342375 id: 2024-0434 id: A538500 type: OTHER domain: UW- Madison id: Protocol Version 3/20/2024 type: OTHER domain: UW- Madison id: SMPH/POP HEALTH SCI/POP HLTH type: OTHER domain: UW- Madison briefTitle: Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-03 date: 2026-06 date: 2024-04-02 date: 2024-04-05 name: University of Wisconsin, Madison class: OTHER name: Covering Wisconsin briefSummary: The goal of this study is to try new outreach methods to improve access to Medicaid for those who lost Medicaid for procedural reasons. The main questions it aims to answer are:
2. What is the effectiveness of outreach using a live call rather than a pre-recorded call? conditions: No Medicaid Coverage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 425000 type: ESTIMATED name: Outbound phone call measure: Number of people who successfully renew their Medicaid coverage within 3 months of receiving the live outbound call measure: Duration of coverage gaps measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the live outbound call measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the pre-recorded outbound call sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06342362 id: SICHN/IRB-001/2024 briefTitle: Magnesium Sulfate in Neonatal HIE" overallStatus: NOT_YET_RECRUITING date: 2024-04-02 date: 2024-10-02 date: 2024-12-02 date: 2024-04-02 date: 2024-04-02 name: Sindh Institute of Child Health and Neonatology class: OTHER briefSummary: The study will investigates the neuroprotective effects of intravenous magnesium sulfate in neonates with hypoxic-ischemic encephalopathy (HIE) at a Karachi tertiary care hospital. Using a randomized clinical trial design, the study targets term and near-term newborns with moderate to severe HIE. Data collection involves obtaining informed consent, preparing and administering magnesium sulfate, and assessing outcomes including mortality and morbidity. The study aims to provide insights into improving patient outcomes and clinical practice for neonatal HIE management. conditions: Neonates With HIE studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 102 type: ESTIMATED name: Magnesium sulfate name: placebo or standard treatment) measure: Neuroprotective effects sex: ALL minimumAge: 1 Day maximumAge: 30 Days stdAges: CHILD facility: SICHN city: Karachi state: Sindh zip: 74201 country: Pakistan name: Naseem Ahmed, FCPS role: CONTACT phone: 03003145554 email: drnaseemkubar@gmail.com lat: 24.8608 lon: 67.0104 hasResults: False
nctId: NCT06342349 id: SIBP-V03-I briefTitle: A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above. overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2024-12-30 date: 2024-12-30 date: 2024-04-02 date: 2024-04-02 name: Shanghai Institute Of Biological Products class: INDUSTRY name: Shaanxi Provincial Center for Disease Control and Prevention briefSummary: To evaluate the safety of administering 1 or 2 doses of the quadrivalent influenza virus split vaccine (MDCK cells) (0.5ml/dose) in individuals aged 6 months and above. conditions: Influenza studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a single center, randomized, double-blind, controlled phase I clinical trial. primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: Quadrivalent influenza virus split vaccine (MDCK cells) name: Quadrivalent influenza virus split vaccine (Chicken embryo) name: Phosphate buffer solution measure: Solicited Adverse Events (AEs) measure: Unsolicited Adverse Events measure: Serious Adverse Events (SAE) measure: Seroconversion rate measure: Ratio of ≥1:40 measure: Geometric mean increase (GMI) sex: ALL minimumAge: 6 Months stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06342336 id: HS-IT101ST01-I briefTitle: HS-IT101 Injection in the Treatment of Advanced Solid Tumors overallStatus: RECRUITING date: 2024-01-18 date: 2026-03-31 date: 2028-03-31 date: 2024-04-02 date: 2024-04-02 name: Qingdao Sino-Cell Biomedicine Co., Ltd. class: INDUSTRY name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences name: The First Hospital of Jilin University name: West China Hospital briefSummary: Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor. conditions: Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 44 type: ESTIMATED name: HS-IT101 Injection measure: Adverse Events (AE) measure: Serious Adverse Events (SAE) measure: Objective Response Rate (ORR) measure: Time-to-response (TTR) measure: Duration of Response (DOR) measure: Disease Control Rate (DCR) measure: Progression-Free-Survival (PFS) measure: Overall Survival (OS) measure: Lymphocyte subpopulation measure: TCR repertoire sex: ALL minimumAge: 18 Days maximumAge: 75 Days stdAges: CHILD facility: Cancer Hospital, Chinese Academy of Medical Sciences status: RECRUITING city: Beijing state: Beijing zip: 100021 country: China name: Ning Li, MD role: CONTACT phone: 86-010-87788713 email: lining@cicams.ac.cn lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06342323 id: IRB00006761-M2023235 id: ONFM-SBRT type: OTHER domain: Peking university third hospital briefTitle: The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy acronym: ONFM-SBRT overallStatus: RECRUITING date: 2023-10-08 date: 2024-10-07 date: 2025-10-07 date: 2024-04-02 date: 2024-04-02 name: Peking University Third Hospital class: OTHER briefSummary: This is a clinical study focused on the use of fiducial marker-guided stereotactic body radiotherapy (SBRT) for treating malignant tumors, including lung, liver, pancreatic, and kidney/adrenal cancers. Here's a breakdown of the key components of the study:
Overall, the study aims to explore the feasibility and effectiveness of using fiducial marker-guided SBRT for treating various types of malignant tumors to assess both the safety and the efficacy with a focus on patient outcomes and treatment accuracy. conditions: Lung Cancer conditions: Liver Cancer conditions: Pancreatic Cancer conditions: Renal Cell Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 57 type: ESTIMATED name: SBRT measure: success rate measure: Treatment error sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University Third Hospital status: RECRUITING city: Beijing state: Beijing zip: 100191 country: China name: Qiu Bin role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06342310 id: RE104-201-PPD briefTitle: RE104 Safety and Efficacy Study in Postpartum Depression overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-06 date: 2024-04-02 date: 2024-04-03 name: Reunion Neuroscience Inc class: INDUSTRY briefSummary: The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo. conditions: Postpartum Depression studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 72 type: ESTIMATED name: RE104 for Injection measure: RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score measure: RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score measure: RE104 30 mg versus RE104 1.5 mg percentage of patients with MADRS response (≥ 50 percent reduction in score from baseline) measure: RE104 30 mg versus RE104 1.5 mg percentage of patients with MADRS remission (score ≤ to 10) measure: RE104 30 mg versus RE104 1.5 mg Clinical Global Impression-Improvement (CGI-I) measure: RE104 30 mg versus RE104 1.5 mg change from baseline in CGI-Severity (CGI-S) measure: RE104 30 mg versus RE104 1.5 mg changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A) measure: RE104 30 mg versus RE104 1.5 mg incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness. sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06342297 id: OLL-1003043 briefTitle: Dermatoscopy Guided Resection for Skin Cancer overallStatus: RECRUITING date: 2024-01-14 date: 2025-12-15 date: 2026-01-14 date: 2024-04-02 date: 2024-04-02 name: Region Örebro County class: OTHER briefSummary: In this randomizid controlled trial the aim is to use dermatoscopy in deciding the resection margin for patients with suspected or verified basal cell carcinoma or cutaneous squamous cell carcinoma. The outcome is radical/non radical resection of the lateral margins in the pathology report. conditions: Basal Cell Carcinoma conditions: Cutaneous Squamous Cell Carcinoma conditions: Surgical Margin studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 400 type: ESTIMATED name: Dermatoscopy measure: Pathology resection side margin (radical/not radical) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Örebro University Hospital status: RECRUITING city: Örebro zip: 70375 country: Sweden name: Örebro U Hospital role: CONTACT phone: 0729655663 email: fredrik.landstrom@regionorebrolan.se lat: 59.27412 lon: 15.2066 hasResults: False
nctId: NCT06342284 id: NYPC ERC# 2021-030 briefTitle: Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer acronym: PGHD overallStatus: RECRUITING date: 2024-03-22 date: 2026-03-21 date: 2031-03-21 date: 2024-04-02 date: 2024-04-02 name: The New York Proton Center class: OTHER briefSummary: This is an observational study involving the collection of patient-generated health data using an Apple Watch, a home pulse oximeter, and a smartphone during a course of proton beam radiotherapy for lung cancer. The study period over which this information is collected will range from the day of study enrollment until two weeks after radiotherapy completion. Subjects will complete a short satisfaction survey at the end of the study period. Other information that is collected as part of routine care for this patient population will be extracted from subjects' medical records during the study period and afterwards. conditions: Thoracic Cancer studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Proton Beam Radiation with or without concurrent chemotherapy measure: Demonstrate the feasibility of patient-generated health data collection during thoracic proton beam radiotherapy for lung cancer, based on the quantity of data collected from the day of radiotherapy initiation to the day of radiotherapy completion. measure: Demonstrate the face validity of physical activity and vital sign data collected in this trial by reviewing the distribution of values obtained for each measure quantitatively using descriptive statistics. measure: Assess associations between radiotherapy treatment parameters, wearable device data, patient-reported outcomes, adverse events, and long-term clinical outcomes using inferential statistical analyses. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: New York Proton Center status: RECRUITING city: New York state: New York zip: 10035 country: United States name: Ryan Holder, BS role: CONTACT phone: 646-968-9055 email: rholder@nyproton.com name: Thomas Mistretta, MS role: CONTACT phone: 646-568-5675 email: tmistretta@nyproton.com name: Nitin Ohri, MD role: PRINCIPAL_INVESTIGATOR name: Charles Simone, MD role: SUB_INVESTIGATOR name: Annemarie Shepherd, MD role: SUB_INVESTIGATOR name: Stanislav Lazarev, MD role: SUB_INVESTIGATOR name: Alexandra Hanlon, PhD role: SUB_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06342271 id: 24-2023 briefTitle: Effects of Nordic Walking and Free Walking on Arm Swing Parameters and Gait in Parkinson's Disease overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-03-30 date: 2025-06-30 date: 2024-04-02 date: 2024-04-02 name: University of Talca class: OTHER briefSummary: People with Parkinson's Disease(PD) present a series of alterations such as muscle stiffness and motor slowing, which gradually affect the swinging movement of the arms and legs, altering the ability to walk, increasing the risk of falling, and reducing functionality. This implies a higher energy cost and a greater probability of developing freezing of the gait.
People with PD will complete 24 supervised NW or FW training sessions for 12 weeks. Both trainings will be identical in volume and intensity, the only difference will be the use of poles in the NW group. Blinded researchers will conduct evaluations at baseline (T0), post-intervention (T1), and in one-month follow-up (T2). conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 28 type: ESTIMATED name: Nordic walking training name: Free Walking training measure: Change in the amplitude of arm swing measure: Change in the arm swing asymmetry measure: Change in the temporospatial measurements during walking including measurements of Gait speed [m/s] and step length [m]. measure: Change in the functional mobility will be measured through the Timed up and go (TUG). measure: Change in the quality of life sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False